3-amino-3-(3,5-dimethylphenyl)propanoic acid | 293330-11-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-amino-3-(3,5-dimethylphenyl)propanoic acid
• 英文别名: 3-azaniumyl-3-(3,5-dimethylphenyl)propanoate
• CAS: 293330-11-7
• 化学式: C₁₁H₁₅NO₂
• 分子量: 193.246
• InChiKey: YBIJIOITROSVBG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.2
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-amino-3-(3,5-dimethylphenyl)propanoic acid 在 盐酸 、 immobilized Pseudomonas cepacia lipase 作用下， 以 various solvent(s) 为溶剂， 反应 24.0h， 生成 乙基(3R)-3-氨基-3-(3,5-二甲基苯基)丙酸酯
  参考文献：
  名称：

  R-Isomers of Arg-Gly-Asp (RGD) mimics as potent αvβ3 inhibitors

  摘要：

  The integrin alpha(v)beta(3), vitronectin receptor, is expressed in a number of cell types and has been shown to mediate adhesion of osteoclasts to bone matrix, vascular smooth muscle cell migration, and angiogenesis. We recently disclosed the discovery of a tripeptide Arg-Gly-Asp (RGD) mimic, which has been shown to be a potent inhibitor of the integrin alpha(v)beta(3) and has excellent anti-angiogenic properties including its suppression of tumor growth in animal models. In other investigations involving RGD mimics, only compounds containing the S-isomers of the beta-amino acids have been shown to be potent. We were surprised to find the potencies of analogs containing enantiomerically pure S-isomers of beta-amino acids which were only marginally better than the corresponding racemic mixtures. We therefore synthesized RGD mimics containing R-isomers of beta-amino acids and found them to be relatively potent inhibitors of alpha(v)beta(3). One of the compounds was examined in tumor models in mice and has been shown to significantly reduce the rate of growth and the size of tumors. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.03.034
• 作为产物：
  描述：

  丙二酸 、 3,5-二甲基苯甲醛 在 ammonium acetate 作用下， 以 异丙醇 为溶剂， 以47%的产率得到3-amino-3-(3,5-dimethylphenyl)propanoic acid
  参考文献：
  名称：

  Structure Activity Relationships of α_v Integrin Antagonists for Pulmonary Fibrosis by Variation in Aryl Substituents

  摘要：

  Antagonism of alpha(v)beta(6) is emerging as a potential treatment of idiopathic pulmonary fibrosis based on strong target validation. Starting from an alpha(v)beta(3) antagonist lead and through simple variation in the nature and position of the aryl substituent, the discovery of compounds with improved alpha(v)beta(6) activity is described. The compounds also have physicochemical properties commensurate with oral bioavailability and are high quality starting points for a drug discovery program. Compounds 33S and 43E1 are pan av antagonists having ca. 100 nM potency against alpha(v)beta(3), alpha(v)beta(5), alpha(v)beta(6), and av beta 8 in cell adhesion assays. Detailed structure activity relationships with these integrins are described which also reveal substituents providing partial selectivity (defined as at least a 0.7 log difference in pIC(50) values between the integrins in question) for alpha(v)beta(3) and alpha(v)beta(5).

  DOI：

  10.1021/ml5002079

文献信息

• DIAMINOPROPANE DERIVED MACROCYCLES AS INHIBITORS OF BETA AMYLOID PRODUCTION
  申请人：Marcin Lawrence R.

  公开号：US20080194535A1

  公开（公告）日：2008-08-14

  There is provided a series of macrocyclic diaminopropanes of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , m, n, W, X, Y, Z and L as defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to β-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.

  提供一系列宏环脂肪二胺丙烷化合物的化学式（I）或其立体异构体；或其药用盐， 其中R1，R2，R3，m，n，W，X，Y，Z和L如本文所定义，它们的药物组合物和使用方法。这些新化合物抑制β-分泌酶对淀粉样前体蛋白（APP）的加工，更具体地说，抑制Aβ-肽的产生。本公开涉及对治疗与β-淀粉样蛋白产生相关的神经系统疾病的化合物，如阿尔茨海默病和其他受抗淀粉样活性影响的疾病。
• Diaminopropane derived macrocycles as inhibitors of β amyloid production
  申请人：Bristol-Meyers Squibb Company

  公开号：US07772221B2

  公开（公告）日：2010-08-10

  There is provided a series of macrocyclic diaminopropanes of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, m, n, W, X, Y, Z and L as defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to β-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.

  提供了一系列的宏环二胺丙烷化合物，其化学式为(I)或其立体异构体，或其药学上可接受的盐。其中，R1、R2、R3、m、n、W、X、Y、Z和L的定义如本文所述，以及它们的药物组合物和使用方法。这些新颖化合物能够抑制β-分泌酶对淀粉样前体蛋白(APP)的加工作用，更具体地抑制Aβ肽的产生。本发明涉及在治疗与β-淀粉样蛋白产生有关的神经系统疾病，如阿尔茨海默病和其他受抗淀粉样蛋白活性影响的疾病中有用的化合物。
• US7772221B2
  申请人：——

  公开号：US7772221B2

  公开（公告）日：2010-08-10
• R-Isomers of Arg-Gly-Asp (RGD) mimics as potent αvβ3 inhibitors
  作者：Srinivasan R. Nagarajan、Balekudru Devadas、James W. Malecha、Hwang-Fun Lu、Peter G. Ruminski、Joseph G. Rico、Thomas E. Rogers、Laura D. Marrufo、Joe T. Collins、H. Peter Kleine

  DOI：10.1016/j.bmc.2007.03.034

  日期：2007.6.1

  The integrin alpha(v)beta(3), vitronectin receptor, is expressed in a number of cell types and has been shown to mediate adhesion of osteoclasts to bone matrix, vascular smooth muscle cell migration, and angiogenesis. We recently disclosed the discovery of a tripeptide Arg-Gly-Asp (RGD) mimic, which has been shown to be a potent inhibitor of the integrin alpha(v)beta(3) and has excellent anti-angiogenic properties including its suppression of tumor growth in animal models. In other investigations involving RGD mimics, only compounds containing the S-isomers of the beta-amino acids have been shown to be potent. We were surprised to find the potencies of analogs containing enantiomerically pure S-isomers of beta-amino acids which were only marginally better than the corresponding racemic mixtures. We therefore synthesized RGD mimics containing R-isomers of beta-amino acids and found them to be relatively potent inhibitors of alpha(v)beta(3). One of the compounds was examined in tumor models in mice and has been shown to significantly reduce the rate of growth and the size of tumors. (c) 2007 Elsevier Ltd. All rights reserved.
• Structure Activity Relationships of α_v Integrin Antagonists for Pulmonary Fibrosis by Variation in Aryl Substituents
  作者：James Adams、Edward C. Anderson、Emma E. Blackham、Yin Wa Ryan Chiu、Thomas Clarke、Natasha Eccles、Luke A. Gill、Joshua J. Haye、Harvey T. Haywood、Christian R. Hoenig、Marius Kausas、Joelle Le、Hannah L. Russell、Christopher Smedley、William J. Tipping、Tom Tongue、Charlotte C. Wood、Jason Yeung、James E. Rowedder、M. Jonathan Fray、Thomas McInally、Simon J. F. Macdonald

  DOI：10.1021/ml5002079

  日期：2014.11.13

  Antagonism of alpha(v)beta(6) is emerging as a potential treatment of idiopathic pulmonary fibrosis based on strong target validation. Starting from an alpha(v)beta(3) antagonist lead and through simple variation in the nature and position of the aryl substituent, the discovery of compounds with improved alpha(v)beta(6) activity is described. The compounds also have physicochemical properties commensurate with oral bioavailability and are high quality starting points for a drug discovery program. Compounds 33S and 43E1 are pan av antagonists having ca. 100 nM potency against alpha(v)beta(3), alpha(v)beta(5), alpha(v)beta(6), and av beta 8 in cell adhesion assays. Detailed structure activity relationships with these integrins are described which also reveal substituents providing partial selectivity (defined as at least a 0.7 log difference in pIC(50) values between the integrins in question) for alpha(v)beta(3) and alpha(v)beta(5).